#WCLC21: AstraZeneca's EGFR inhibitor Tagrisso cuts relapse, death risks in patients with and without prior chemotherapy
AstraZeneca’s Tagrisso has established a strong foothold in non-small cell lung cancer — the largest section of the lung cancer community — with multiple approvals in the early setting. Those approvals include patients with removed tumors, an indication where physicians have gone back and forth on the use of chemotherapy.
Now, AstraZeneca may have an answer for the chemo debate: It doesn’t really matter in terms of our drug’s efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.